Six novel susceptibility loci for early-onset androgenetic alopecia and their unexpected association with common diseases

PLoS Genetics

Volumn 8, Issue 5, 2012, Pages

  Li, Rui ^a   Brockschmidt, Felix F ^b   Kiefer, Amy K ^c   Stefansson, Hreinn ^d   Nyholt, Dale R ^e   Song, Kijoung ^f   Vermeulen, Sita H ^g   Kanoni, Stavroula ^h   Glass, Daniel ⁱ   Medland, Sarah E ^e   Dimitriou, Maria ^j   Waterworth, Dawn ^f   Tung, Joyce Y ^c   Geller, Frank ^k   Heilmann, Stefanie ^b   Hillmer, Axel M ^l   Bataille, Veronique ⁱ   Eigelshoven, Sibylle ^m   Hanneken, Sandra ^m   Moebus, Susanne ⁿ   Herold, Christine ^o   den Heijer, Martin ^g   Montgomery, Grant W ^e   Deloukas, Panos ^h   Eriksson, Nicholas ^c   Heath, Andrew C ^p   Becker, Tim ^b,o   Sulem, Patrick ^d   Mangino, Massimo ⁱ   Vollenweider, Peter ^q   Spector, Tim D ⁱ   Dedoussis, George ^j   Martin, Nicholas G ^e   Kiemeney, Lambertus A ^g,r   Mooser, Vincent ^f   Stefansson, Kari ^d   Hinds, David A ^c   Nöthen, Markus M ^b,o   Richards, J Brent ^a,i   more..

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BONN   (Germany)

^c 23andMe ^*  (United States)

^d DECODE GENETICS   (Iceland)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f GLAXOSMITHKLINE   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j HAROKOPIO UNIVERSITY   (Greece)

^k STATENS SERUM INSTITUT   (Denmark)

^l GENOME INSTITUTE OF SINGAPORE   (Singapore)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^r Integraal Kankercentrum Oost   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 4;

ALLELE; AR GENE; ARTICLE; AUTISM SUSCEPTIBILITY CANDIDATE 2 GENE; CHROMOSOME 17Q; CHROMOSOME 20; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HDAC9 GENE; HISTONE DEACETYLASE 4 GENE; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; MALE TYPE ALOPECIA; MUTATOR GENE; ONSET AGE; PARKINSON DISEASE; X CHROMOSOME;

ADULT; AGED; ALLELES; ALOPECIA; FERTILITY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84863698179     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002746     Document Type: Article

References (62)

1. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
2. Donoso LA, Vrabec T, Kuivaniemi H, (2010) The role of complement Factor H in age-related macular degeneration: a review. Surv Ophthalmol 55: 227-246.
3. Richards JB, Yuan X, Geller F, Waterworth D, Bataille V, et al. (2008) Male-pattern baldness susceptibility locus at 20p11. Nat Genet 40: 1282-1284.
4. Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S, Steffens M, et al. (2008) Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 40: 1279-1281.
5. Hamilton JB, (1951) Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 53: 708-728.
6. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, et al. (2006) Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91: 1357-1363.
7. Giles GG, Severi G, Sinclair R, English DR, McCredie MR, et al. (2002) Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 11: 549-553.
8. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8-29.
9. Heinlein CA, Chang C, (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
10. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, et al. (2009) Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet 5: e1000597 doi:10.1371/journal.pgen.1000597.
11. Lu Y, Zhang Z, Yu H, Zheng SL, Isaacs WB, et al. (2011) Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate 71: 955-963.
12. Ellis JA, Sinclair R, Harrap SB, (2002) Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 4: 1-11.
13. Suzuki H, Ueda T, Ichikawa T, Ito H, (2003) Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10: 209-216.
14. Hayes VM, Severi G, Eggleton SA, Padilla EJ, Southey MC, et al. (2005) The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 14: 993-996.
15. Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, et al. (2007) 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer 120: 776-780.
16. Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, et al. (2010) Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur J Cancer 46: 3294-3299.
17. Wright JL, Page ST, Lin DW, Stanford JL, (2010) Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol 34: 131-135.
18. Yassa M, Saliou M, De Rycke Y, Hemery C, Henni M, et al. (2011) Male pattern baldness and the risk of prostate cancer. Ann Oncol.
19. Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, et al. (2005) Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann N Y Acad Sci 1061: 77-93.
20. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, et al. (2006) Expression and role of Foxa proteins in prostate cancer. Prostate 66: 1013-1028.
21. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, et al. (2010) Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18: 23-38.
22. Yu X, Wang Y, Degraff DJ, Wills ML, Matusik RJ, (2011) Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30: 1868-1879.
23. Martin M, Kettmann R, Dequiedt F, (2007) Class IIa histone deacetylases: regulating the regulators. Oncogene 26: 5450-5467.
24. Jeong BC, Hong CY, Chattopadhyay S, Park JH, Gong EY, et al. (2004) Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Mol Endocrinol 18: 13-25.
25. Suh JH, Shong M, Choi HS, Lee K, (2008) CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction. Mol Endocrinol 22: 33-46.
26. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN, (2004) Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. European urology 45: 382-389; author reply 389.
27. Petrie K, Guidez F, Howell L, Healy L, Waxman S, et al. (2003) The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 278: 16059-16072.
28. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, et al. (2001) ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21: 6470-6483.
29. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, et al. (2011) Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 43: 570-573.
30. Schumann G, Coin LJ, Lourdusamy A, Charoen P, Berger KH, et al. (2011) Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. Proc Natl Acad Sci U S A 108: 7119-7124.
31. Herold C, Steffens M, Brockschmidt FF, Baur MP, Becker T, (2009) INTERSNP: genome-wide interaction analysis guided by a priori information. Bioinformatics 25: 3275-3281.
32. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, et al. (2007) New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871-878.
33. Hu S, Yao G, Guan X, Ni Z, Ma W, et al. (2010) Research resource: Genome-wide mapping of in vivo androgen receptor binding sites in mouse epididymis. Mol Endocrinol 24: 2392-2405.
34. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, et al. (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74: 97-109.
35. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
36. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781-785.
37. Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, et al. (2011) Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 20: 345-353.
38. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377: 641-649.
39. Do CB TJ, Dorfman E, Kiefer AK, Drabant EM, et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 7: e1002141 doi:10.1371/journal.pgen.1002141.
40. de Lau LM, Breteler MM, (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535.
41. Miwa H, Kondo T, (2003) Hair loss induced by dopamine agonist: case report and review of the literature. Parkinsonism Relat Disord 10: 51-52.
42. Cunningham RL, Giuffrida A, Roberts JL, (2009) Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta. Endocrinology 150: 5539-5548.
43. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, et al. (2003) Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157: 1015-1022.
44. Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, et al. (2005) A common inversion under selection in Europeans. Nat Genet 37: 129-137.
45. Voight BF, Kudaravalli S, Wen X, Pritchard JK, (2006) A map of recent positive selection in the human genome. PLoS Biol 4: e72 doi:10.1371/journal.pbio.0040072.
46. Nestler JE, (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358: 47-54.
47. Carey AH, Waterworth D, Patel K, White D, Little J, et al. (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3: 1873-1876.
48. Govind A, Obhrai MS, Clayton RN, (1999) Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 84: 38-43.
49. Pastor P, Ezquerra M, Perez JC, Chakraverty S, Norton J, et al. (2004) Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann Neurol 56: 249-258.
50. Rademakers R, Cruts M, van Broeckhoven C, (2004) The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24: 277-295.
51. Schrag A, Ben-Shlomo Y, Quinn NP, (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354: 1771-1775.
52. Togasaki DM, Tanner CM, (2000) Epidemiologic aspects. Adv Neurol 82: 53-59.
53. Ratnavalli E, Brayne C, Dawson K, Hodges JR, (2002) The prevalence of frontotemporal dementia. Neurology 58: 1615-1621.
54. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, et al. (2010) Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 42: 570-575.
55. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR, (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34: 816-834.
56. Marchini J, Howie B, Myers S, McVean G, Donnelly P, (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39: 906-913.
57. Magi R, Morris AP, (2010) GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics 11: 288.
58. Balding DJ, (2006) A tutorial on statistical methods for population association studies. Nat Rev Genet 7: 781-791.
59. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
60. (2011) A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 43: 339-344.
61. Cuzick J, (1985) A Wilcoxon-type test for trend. Stat Med 4: 87-90.
62. Yu W, Yesupriya A, Wulf A, Hindorff LA, Dowling N, et al. (2011) GWAS Integrator: a bioinformatics tool to explore human genetic associations reported in published genome-wide association studies. Eur J Hum Genet 19: 1095-1099.